Evidence Hub

Bridging in vitro buoyancy to clinical performance: A PBPK-driven analysis of once-daily Bepotastine gastro-retentive tablet in beagles and humans

Jeong-Soo Kim, Heejun Park, Eun-Sol Ha, In-hwan Baek, Min-Soo Kim

Journal of Controlled Release, 2026

28 participants

Abstract

Bepotastine possesses a short half-life (~2 h) and a narrow absorption window limited to the upper small intestine, necessitating a gastro-retentive drug delivery system for once-daily administration. In this study, we developed a low-density gastro-retentive tablet designed for instantaneous floating (zero lag time) to prevent premature gastric emptying-a critical limitation of conventional floating systems. This was achieved through a rational engineering approach using AutoCAD-based geometric integration to precisely control the initial apparent density below 1.004 g/cm3. The synergistic combination of low viscosity hypromellose (15 cP) and magnesium aluminometasilicate facilitated immediate buoyancy and sustained it for over 4 h through wicking-induced air entrapment and robust gel layer formation. In beagle dogs, the gastro-retentive tablet achieved 95.7% systemic exposure relative to a twice-daily reference, whereas non-floating sustained-release formulations reached only 64.5-88.6%, highlighting the necessity of gastric retention. Notably, a randomized clinical study in 28 healthy subjects confirmed that the scaled-up gastro-retentive formulation was bioequivalent to the reference product. Produced via standard manufacturing processes, the 100,000-tablet batch also demonstrated no clinically significant food effect. Species-specific physiologically based pharmacokinetic modeling mechanistically estimated gastric residence times of approximately 180 min in beagles and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free